Dark Forest Capital Management LP Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Dark Forest Capital Management LP acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 1,884 shares of the company's stock, valued at approximately $626,000.

A number of other large investors have also recently made changes to their positions in MEDP. R Squared Ltd bought a new stake in shares of Medpace in the 4th quarter worth approximately $30,000. SBI Securities Co. Ltd. purchased a new position in shares of Medpace in the 4th quarter valued at approximately $31,000. Jones Financial Companies Lllp lifted its stake in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the period. Finally, Assetmark Inc. lifted its stake in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Insider Activity

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now owns 2,998 shares in the company, valued at approximately $904,856.36. This trade represents a 36.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.30% of the company's stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research analyst reports. Leerink Partnrs upgraded Medpace to a "hold" rating in a research note on Monday, March 24th. William Blair restated a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd. Robert W. Baird lowered their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Finally, Truist Financial lowered their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research note on Wednesday, April 23rd. Eleven analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Medpace currently has an average rating of "Hold" and an average price target of $349.30.

Medpace Price Performance

Shares of MEDP traded down $3.51 during trading hours on Thursday, hitting $304.89. The stock had a trading volume of 161,058 shares, compared to its average volume of 340,976. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $459.77. The firm has a market capitalization of $8.76 billion, a PE ratio of 24.14, a PEG ratio of 3.81 and a beta of 1.46. The stock has a fifty day moving average price of $311.46 and a 200 day moving average price of $330.93.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The company had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. During the same quarter in the previous year, the company posted $3.20 earnings per share. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.